AlphaYouJG
Congress trade
Rep. Josh Gottheimer (D-NJ) bought $1K-$15K of BioCryst Pharmaceuticals, Inc. (BCRX) stock
Josh Gottheimer, U.S. Representative (D-NJ), disclosed a purchase of BioCryst Pharmaceuticals, Inc. (BCRX) stock worth $1K-$15K in a STOCK Act filing on Sep 16, 2022.
The trade happened on Aug 11, 2022, 36 days before it was made public.
BCRX has moved -43.1% since the trade date, from $14.37 to $8.17 (Oct 2, 2026 close).
- Traded
- Aug 11, 2022
- Disclosed
- Sep 16, 2022
- Filing delay
- 36 days
- Price since
- -43.1%
- Source
- STOCK Act disclosure
Other trades in this disclosure (29)
- BuyMSFT$1M-$5MSep 16, 2022
- BuyMSFT$1M-$5MSep 16, 2022
- BuyMSFT$1M-$5MSep 16, 2022
- SellMSFT$1M-$5MSep 16, 2022
- SellMSFT$1M-$5MSep 16, 2022
- SellMSFT$1M-$5MSep 16, 2022
- BuyMSFT$250K-$500KSep 16, 2022
- BuyMSFT$250K-$500KSep 16, 2022
- BuyMSFT$250K-$500KSep 16, 2022
- SellMSFT$250K-$500KSep 16, 2022
- SellMSFT$250K-$500KSep 16, 2022
- SellMSFT$250K-$500KSep 16, 2022
- SellMSFT$100K-$250KSep 16, 2022
- BuyMSFT$100K-$250KSep 16, 2022
- SellMSFT$100K-$250KSep 16, 2022
- SellAAPL$1K-$15KSep 16, 2022
- BuyADP$1K-$15KSep 16, 2022
- SellBX$1K-$15KSep 16, 2022
- SellCCXI$1K-$15KSep 16, 2022
- SellCRNC$1K-$15KSep 16, 2022
More BCRX insider and Congress trades
From a public STOCK Act disclosure, linked above. Not investment advice, and not a recommendation to buy or sell.